Preview

Messenger of ANESTHESIOLOGY AND RESUSCITATION

Advanced search

Ways to optimize infusion therapy for diabetic ketoacidosis

https://doi.org/10.24884/2078-5658-2025-22-2-68-75

Abstract

Introduction. The problem of endothelioprotection is currently highly relevant for critical care medicine. The effect of diabetic ketoacidosis on the state of endothelial glycocalyx has not been sufficiently studied. The effectiveness of infusion therapy in the treatment of diabetic ketoacidosis is determined by the functional state of the endothelium.

The objective was to evaluate the effectiveness of meglumine sodium succinate used in the infusion therapy of diabetic ketoacidosis for correction of endothelial glycocalyx dysfunction Materials and methods. The prospective study included 50 patients with diabetic ketoacidosis, divided into 2 groups – the first, where 0.9% sodium chloride was used as an infusion solution, the second, where meglumine sodium succinate (Reamberin) was added to the infusion program at a daily dose of 10 ml /kg. Two control groups were also examined: 20 healthy volunteers and 20 people with diabetes mellitus without a history of critical complications. Their randomization was carried out using the blind envelope method. We studied the levels of syndecan-1 in blood plasma and the albumin-creatinine ratio of urine (hereinafter referred to as ACR) at baseline in all groups, as well as in the study groups (№ 1 and № 2) during intensive care.

Results. Syndecan-1 and ACR levels were lowest in the group of healthy volunteers. In the group of people with diabetes mellitus without critical complications, the level of these markers was statistically significant higher than in healthy volunteers. The highest values of syndecan-1 and ACR markers were in the groups of patients with diabetic ketoacidosis, and at the initial time point, they were representative of each other in both groups. During the study, it was revealed that in the group with the inclusion of Reamberin (group No. 2), the levels of syndecan-1 and ACR were lower in dynamics than in the group using 0.9% sodium chloride exclusively (group No. 1). The maximum difference was reached by 48 hours of intensive care and was 19.3% for syndecan-1 and 17.5% for ACR.

Conclusion. The use of polyionic crystalloid solution Reamberin as part of infusion therapy has a positive effect on the state of glycocalyx during intensive care, which reduces the severity of capillary leakage syndrome.

About the Authors

M. I. Neimark
Altai State Medical University
Russian Federation

Neimark Mikhail I., Dr. of Sci. (Med.), Professor, Honored Doctor of the Russian Federation, Head of the Department of Anesthesiology and Intensive Care with a Course of Additional Professional Education

40, Lenin pr., Barnaul, 656038



E. A. Kloster
Russian Railways-Medicine Clinical Hospital of Barnaul
Russian Federation

Kloster Evgeny A., Anesthesiologist and Intensivist

20, Molodezhnaya str., Barnaul, 656038



A. A. Bulganin
Russian Railways-Medicine Clinical Hospital of Barnaul
Russian Federation

Bulganin Andrey A., Cand. of Sci. (Med.), Head of the Department of Anesthesiology and Intensive Care

20, Molodezhnaya str., Barnaul, 656038



A. E. Zavyalov
Altai State Medical University; Altai Regional Center for Maternal and Child Health
Russian Federation

Zavyalov Alexey Egorovich, Dr. of Sci. (Med.), Chief Pediatric Anesthesiologist and Intensivist, Head of the Department of Anesthesiology and Intensive Care; Professor of the Department of Neonatology and Pediatric Anesthesiology with a Course of Additional Professional Education

40, Lenin pr., Barnaul, 656038

179, Gushchin str., Barnaul, 656019



References

1. Vlasov T. D., Lazovskaya O. A., Szymanski D. A., Nesterovich I. I., Shaporova N. L. Endothelial glycocalyx: research methods and prospects for their application in the assessment of endothelial dysfunction. Regional blood circulation and microcirculation, 2020, vol. 19, no. 1, pp. 5–16. (In Russ.). https://doi.org/10.24884/1682-6655-2020-19-1-5-16.

2. Vorobyeva A. P., Bykov Yu. V., Baturin V. A., Muravyeva A. A. Markers of glycocalyx damage in complications of diabetes mellitus. Modern problems of science and education, 2023, no. 4. (In Russ.). https://doi.org/10.17513/spno.32783.

3. Dedov I. I., Shestakova M. V., Vikulova O. K. et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010-2022. Diabetes mellitus, 2023, vol. 26, no. 2, pp. 104–123. (In Russ.). https://doi.org/10.14341/DM13035.

4. Dedov I. I., Shestakova M. V., Mayorov A. Yu. Algorithms of specialized medical care for patients with diabetes mellitus – 10th edition (expanded). Moscow, 2021. (In Russ.). https://doi.org/10.14341/DM12802.

5. Zabolotskikh I. B., Protsenko D. N. Intensive care: national guidelines. vol. 2 : in 2 volumes - 2nd ed., revised. and add. Moscow: GEOTAR-Media, 2022. 1056 P. (In Russ.). https://doi.org/10.33029/9704-5018-5. ICNG-2020-1-1056. ISBN 978-5-9704-6259-1.

6. Ivanova N. A., Leiderman I. N., Malkov N. N., Nerush A. S. Key markers of “capillary leakage” in sepsis and septic shock. Creative surgery and oncology, 2017, vol. 7, no. 1, pp. 15–19. (In Russ.). https://doi.org/10.24060/2076-3093-2017-7-1-15-19.

7. Kalinichenko A. P., Lomivorotov V. V., Kornilov I. A., Knyazkova L. G. The prognostic role of markers of endothelial dysfunction and capillary leakage syndrome in myocardial revascularization surgery under conditions of artificial circulation. Bulletin of New Medical Technologies, 2011, vol. XVIII, no. 2, pp. 390–392. (In Russ.).

8. Simutis I. S., Ratnikov V. A., Shcheglov A. N. et al. Systemic inflammatory response and COVID-19–mediated endothelial dysfunction - common solutions. Therapeutic Archive, 2023, vol. 95, no. 6, pp. 487–493. (In Russ.). https://doi.org/10.26442/00403660.2023.6.202232.

9. Sokologorskiy S. V. Glycocalyx — the birth of a new clinical paradigm. Anesthesiology and intensive care, 2018, vol. 4, pp. 22–29. (In Russ.). https://doi.org/10.17116/anaesthesiology201804122.

10. Tikhonova E. O., Lyapina E. P., Shuldyakov A. A., Satarova S. A. The use of preparations containing succinate in the clinic of infectious diseases. Therapeutic Archive, 2016, vol. 88, no. 11, pp. 121–127. (In Russ.). https://doi.org/10.17116/terarkh20168811121-127.

11. Shah B. N., Lapshin V. N., Kirnyshev A. G. et al. Metabolic effects of a substrate antihypoxant based on succinic acid. General resuscitation. 2014. № 1. (In Russ.). https://doi.org/10.15360/1813-9779-2014-1-33-42.

12. Becker B. F., Chappell D., Jacob M. Endothelial glycocalyx and coronary vascular permeability: the fringe benefit. Basic Res Cardiol, 2010, vol. 105, pp. 687. https://doi.org/10.1007/s00395-010-0118-z.

13. Bihari S., Wiersema U. F., Perry R. et al. Efficacy and safety of 20% albumin fluid loading in healthy subjects: a comparison of four resuscitation fluids. J Appl Physiol, 2019, vol. 126, pp. 1646–60. https://doi.org/10.1152/japplphysiol.01058.2018.

14. Jahangir A., Jahangir A., Siddiqui F. et al. Normal Saline Versus Low Chloride Solutions in Treatment of Diabetic Ketoacidosis: A Systematic Review of Clinical Trials. Cureus, 2022, vol. 14, no. 1, pp. e21324. https://doi.org/10.7759/cureus.2132.

15. Johansson P. I., Stensballe J., Rasmussen L. S., Ostrowski S. R. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg, 2011, vol. 254, no. 2, pp. 194–200. https://doi.org/10.1097/SLA.0b013e318226113d.

16. Patterson E. K., Cepinskas G., Fraser D. D. Endothelial Glycocalyx Degradation in Critical Illness and Injury. Front. Med, 2022, vol. 9, pp. 898592. https://doi.org/10.3389/fmed.2022.898592.

17. Pries A. R., Secomb T. W., Gaehtgens P. The endothelial surface layer. Pflügers Arch Eur J Physiol, 2000, vol. 440, pp. 653. https://doi.org/10.1007/s004240000307.

18. Wang J. B., Zhang Y. J., Zhang Y. et al. Negative correlation between serum syndecan-1 and apolipoprotein A1 in patients with type 2 diabetes mellitus. Acta Diabetol, 2013, vol. 50, pp. 111–115. https://doi.org/10.1007/s00592-010-0216-2.


Review

For citations:


Neimark M.I., Kloster E.A., Bulganin A.A., Zavyalov A.E. Ways to optimize infusion therapy for diabetic ketoacidosis. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2025;22(2):68-75. (In Russ.) https://doi.org/10.24884/2078-5658-2025-22-2-68-75



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2078-5658 (Print)
ISSN 2541-8653 (Online)